
 Scientific claim: Pre-mRNAs associated with spliceosomal components are more stable than unassociated splicing substrates. 
 Participant Dynamics: Originator vs. Interpreter 
 Contextual Arena: The Exploratory Arena (goal: to brainstorm and understand) 
 Interaction Trigger: An External Mandate (a new law, policy, or trend) 
 Dialogue Objective: To Define the Disagreement (map out points of conflict) 
```
Dr. Lewis: So, Dr. Kim, this new policy mandates that we reconsider the stability of pre-mRNAs, specifically those associated with spliceosomal components. They claim these are more stable than unassociated splicing substrates. What's your take?

Dr. Kim: Well, Dr. Lewis, I've been reviewing the data. Iâ€™m skeptical. The stability of pre-mRNAs is complex and context-dependent. Simply associating with spliceosomes doesn't guarantee increased stability.

Dr. Lewis: Interesting. The policy seems to hinge on this claim to direct funding and research priorities. They argue that this could revolutionize therapeutic RNA interventions.

Dr. Kim: I understand the potential implications. But, without robust evidence, shifting resources could be premature. What if the data supporting this stability is inconclusive or context-specific?

Dr. Lewis: True, but proponents point to recent studies that show increased lifespan for these associated pre-mRNAs in certain cellular environments. They argue it's a trend worth pursuing.

Dr. Kim: Ah, but those studies often overlook other interacting factors. The cellular environment is dynamic. What stabilizes RNA in one context might not apply in another. It's not a one-size-fits-all situation.

Dr. Lewis: So, you'd recommend a more cautious approach? Perhaps call for more comprehensive studies before full implementation?

Dr. Kim: Precisely. We need to map out the full picture. Overcommitting resources based on an incomplete understanding could lead to misguided research efforts.

Dr. Lewis: I see your point. So, the disagreement here is about the interpretation of data and its implications for policy. We need a balanced view to guide this mandate effectively.

Dr. Kim: Exactly. We should advocate for a nuanced approach in the policy to allow for further exploration and validation. Science thrives on skepticism and rigor, after all.

Dr. Lewis: Agreed. Let's draft a proposal for a phased research initiative, ensuring we address these uncertainties. 
```